Sandbox/AL: Difference between revisions

Jump to navigation Jump to search
Line 353: Line 353:
<font color="#FFF">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''''Staphylococcus epidermidis'''''
&nbsp;&nbsp;▸&nbsp;&nbsp;'''''Staphylococcus epidermidis'''''
</font>
</div>
<div class="mw-customtoggle-table14" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 300px; background: #4479BA;">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''''Methicillin-resistant S. aureus'''''
</font>
</font>
</div>
</div>
Line 392: Line 386:
</div>
</div>


<div class="mw-customtoggle-table20" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 300px; background: #4479BA;">
<div class="mw-customtoggle-table24" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 300px; background: #4479BA;">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''''Nocardia'''''
</font>
</div>
 
<div class="mw-customtoggle-table23" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 300px; background: #4479BA;">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''''T. whipplei'''''
</font>
</div>
 
<div style="border-radius: 5px 5px 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 300px; background: #A1BCDD; text-align: center;">
<font color="#FFF">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''''Mycobacterium tuberculosis'''''
'''Mycobacteria'''
</font>
</font>
</div>
</div>


<div class="mw-customtoggle-table21" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 300px; background: #4479BA;">
<div class="mw-customtoggle-table20" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 300px; background: #4479BA;">
<font color="#FFF">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''''Borrelia burgdorferi'''''
&nbsp;&nbsp;▸&nbsp;&nbsp;'''''Mycobacterium tuberculosis'''''
</font>
</font>
</div>
</div>


<div class="mw-customtoggle-table22" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 300px; background: #4479BA;">
<div style="border-radius: 5px 5px 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 300px; background: #A1BCDD; text-align: center;">
<font color="#FFF">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''''Treponema pallidum'''''
'''Spirochetes'''
</font>
</font>
</div>
</div>


<div class="mw-customtoggle-table23" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 300px; background: #4479BA;">
<div class="mw-customtoggle-table21" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 300px; background: #4479BA;">
<font color="#FFF">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''''T. whipplei'''''
&nbsp;&nbsp;▸&nbsp;&nbsp;'''''Borrelia burgdorferi'''''
</font>
</font>
</div>
</div>


<div class="mw-customtoggle-table24" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 300px; background: #4479BA;">
<div class="mw-customtoggle-table22" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 300px; background: #4479BA;">
<font color="#FFF">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''''Nocardia'''''
&nbsp;&nbsp;▸&nbsp;&nbsp;'''''Treponema pallidum'''''
</font>
</font>
</div>
</div>


| valign=top |
| valign=top |
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table12" style="background: #FFFFFF;"
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table12" style="background: #FFFFFF;"
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''Staphylococcus aureus''}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''Staphylococcus aureus, Methicillin sensitive''}}
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Preferred Regimen
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Preferred Regimen
Line 437: Line 442:
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Dicloxacillin]] 500 mg PO q6h'''' <br> OR <br> ▸ '''''[[Cephalexin]] 500 mg PO q6h''''' <br> OR <br> ▸ '''''[[Clindamycin]] 300 mg PO q8h''''' <br> OR <br> ▸ '''''[[TMP-SMX]] 160-800 mg PO q12h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Dicloxacillin]] 500 mg PO q6h'''' <br> OR <br> ▸ '''''[[Cephalexin]] 500 mg PO q6h''''' <br> OR <br> ▸ '''''[[Clindamycin]] 300 mg PO q8h''''' <br> OR <br> ▸ '''''[[TMP-SMX]] 160-800 mg PO q12h'''''
|-
|-
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''Staphylococcus aureus, Methicillin resistant''}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Preferred Regimen
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 15 mg/kg IV q12h'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Alternative Regimen
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸  '''''[[Linezolid]] 600 mg IV/PO q12h'''''
|}
|}
|}
|}
Line 451: Line 465:
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 15-20 mg/kg IV q8h'''''|}
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 15-20 mg/kg IV q8h'''''|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table14" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''Methicillin-resistant S. aureus''}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Preferred Regimen
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 15 mg/kg IV q12h'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Alternative Regimen
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸  '''''[[Linezolid]] 600 mg IV/PO q12h'''''
|}
|}
|}
|}
Line 651: Line 652:
|}
|}
|}
|}
|}
|}



Revision as of 15:31, 19 May 2014

The treatment for septic arthritis requires an adequate drainage of purulent joint fluid and appropriate antimicrobial therapy. Empiric therapy should be started after the collection joint fluid and blood sample, and these should be send for culture.

Empiric Therapy Adapted from Lancet 375:846, 2010. [1]

▸ Click on the following categories to expand treatment regimens.

  ▸  Pediatric

  ▸  Newborns (< 1 week)

  ▸  Newborns (1 -4 week)

  ▸  Infants (1 - 3 months)

  ▸  Children (3 mo - 14 yr)

  ▸  Adults

  ▸  Acute Monoarticular

  ▸  Chronic Monoarticular

  ▸  Polyarticular

Newborn (< 1 week)
Preferred Regimen
High suspicion of MRSA
Vancomycin 18 mg/kg IV divided q12h
PLUS
Cefotaxime 50 mg/kg IV q12h
Low suspicion of MRSA
Nafcillin 25 mg/kg q8h
OR
Oxacillin 25 mg/kg q8h
PLUS
Cefotaxime 50 mg/kg IV q12h
Alternative Regimen
Clindamycin 5mg/kg q8h
Newborn (1 - 4 weeks)
Preferred Regimen
High suspicion of MRSA
Vancomycin 22 mg/kg q12h
PLUS
Cefotaxime 50 mg/kg IV q8h
Low suspicion of MRSA
Nafcillin 37 mg/kg q6h
OR
Oxacillin 37 mg/kg q6h
PLUS
Cefotaxime 50 mg/kg IV q8h
Alternative Regimen
Clindamycin 5mg/kg q6h
Infants (1- 3 months)
Preferred Regimen
High suspicion of MRSA
Vancomycin 40 mg/kg/day divided q6-8h
PLUS
Cefotaxime 50 mg/kg IV q8h
Low suspicion of MRSA
Nafcillin 37 mg/kg q6h (max 8-12 g/day)
OR
Oxacillin 37 mg/kg q6h (max 8-12 g/day)
PLUS
Cefotaxime 50 mg/kg IV q8h
Alternative Regimen
Clindamycin 7.5mg/kg q6h
Children (3 mo - 14 yr)
Preferred Regimen
Vancomycin 40 mg/kg/day IV q6-8h
PLUS
Cefotaxime 50 mg/kg IV q8h
Alternative Regimen
Linezolid 10 mg/kg IV q8h
OR
Clindamycin 7.5 mg/kg IV q6h
PLUS
Aztreonam 30 mg/kg IV q6h
Acute Monoarticular
Preferred Regimen
At risk for Gonococcal infection
Ceftriaxone 1 g IV q24h
OR
Cefotaxime 1 g IV q8h
OR
Ceftizoxime 1 g IV q8h
Not at risk for Gonococcal infection
Vancomycin 15-20 mg/kg IV q8-12h
PLUS
Ceftriaxone 1g IV q24h
OR
Cefepime 2g IV q8h
Alternative Regimen
(If not at risk for Gonococcal infection)
Vancomycin 15-20 mg/kg IV q8-12h
PLUS
Ciprofloxacin 400 mg IV q12h
OR
Levofloxacin 750 mg IV q24h
Chronic Monoarticular
Empirical therapy is not recommended.
Treatment should be addressed for the specific etiology
Polyarticular
Preferred Regimen
Ceftriaxone 1 gm IV q24h

CSF Gram Stain-Based Therapy Adapted from

▸ Click on the following categories to expand treatment regimens.

Gram-Positive

  ▸  Gram-Positive Cocci

Gram-Negative

  ▸  Gram-Negative Cocci

  ▸  Gram-Negative Rods

  ▸  Negative Gram Stain

Gram-Positive Cocci
Preferred Regimen
Vancomycin 15-20 mg/kg IV q8—12h (trough 15—20 μg/mL)
Alternative Regimen
(For patients allergic to vancomycin)
Linezolid
OR
Daptomycin
Gram-Negative Cocci
Preferred Regimen
Ceftriaxone 1 g IV q24h
Gram-Negative Rods
Preferred Regimen
Ceftazidime 2 g IV q8h
OR
Cefepime 2g IV q12h
OR

Piperacillin-Tazobactam 4.5 g q6h
OR
Imipenem 500 mg IV q6h
OR
Meropenem 1 g IV q8h

Alternative Regimen (For patients allergic to cephalosporins)
Aztreonam 2 g q8h
OR
Ciprofloxacin 400 mg IV q12h
OR
Levofloxacin 750 mg IV q24h
Negative Gram Stain
Preferred Regimen
Vancomycin 15-20 mg/kg IV q8—12h
PLUS
Ceftazidime 2 g IV q8h
Alternative Regimen
Ciprofloxacin 750 mg IV q12h
OR
Levofloxacin 750 mg IV q24h
OR
Tobramycin
OR
Gentamycin 5-7 mg/kg once daily or 5 mg/kg divided in 3 doses/day

Pathogen-Based Therapy — Bacteria Adapted from

▸ Click on the following categories to expand treatment regimens.

Bacteria

  ▸  Staphylococcus aureus

  ▸  Staphylococcus epidermidis

  ▸  Streptococcus groups A, B, C, G

  ▸  Enterococcus feacalis

  ▸  Pseudomonas aeruginosa

  ▸  Neisseria gonorrhoeae

  ▸  Haemophilus influenzae

  ▸  Nocardia

  ▸  T. whipplei

Mycobacteria

  ▸  Mycobacterium tuberculosis

Spirochetes

  ▸  Borrelia burgdorferi

  ▸  Treponema pallidum

Staphylococcus aureus, Methicillin sensitive
Preferred Regimen
Nafcillin 1.5-2 g IV q4h
OR
Oxacillin 1.5-2 g IV q4h
OR
Cefazolin 1 g IV q8h
Alternative Regimen
Dicloxacillin 500 mg PO q6h'
OR
Cephalexin 500 mg PO q6h
OR
Clindamycin 300 mg PO q8h
OR
TMP-SMX 160-800 mg PO q12h
Staphylococcus aureus, Methicillin resistant
Preferred Regimen
Vancomycin 15 mg/kg IV q12h
Alternative Regimen
Linezolid 600 mg IV/PO q12h
Staphylococcus epidermidis
Preferred Regimen
Nafcillin 1.5-2 g IV q4h
OR
Oxacillin 1.5-2 g IV q4h
OR
Cefazolin 1 g IV q8h
Alternative Regimen
Methicillin-resistant
Vancomycin 15-20 mg/kg IV q8h|}
Streptococcus groups A, B, C, G
Preferred Regimen
Penicillin G 20 MU IV q24h or divided in 6 doses/day
OR
Ceftriaxone 2 g IV or IM q24h
OR
Cefazolin 1 g IV q8h
Alternative Regimen
Vancomycin 15mg/kg IV q12h
Enterococcus faecalis
Preferred Regimen
Penicillin G 20 MU IV q24h or divided in 6 doses/day
PLUS
Ampicillin 2 g IV q6h
OR
Gentamicin 1 mg/kg IV or IM q8h
Alternative Regimen
Vancomycin
PLUS
Gentamicin 1 mg/kg IV or IM q8h
Pseudomonas aeruginosa
Preferred Regimen
Ciprofloxacin 750 mg PO q12h
Alternative Regimen
Levofloxacin 500 mg PO q24h
PLUS
Gentamicin 1.7 mg/kg IV q8h
Neisseria gonorrhoeae
Preferred Regimen
Ceftriaxone 1 g IV q24h for 1-2 days after clinical improvement
FOLLOWED BY
Cefixime 400 mg po q12h for 1 week
OR
Ciprofloxacin 500 mg po q12h for 1 week
OR
Ofloxacin 400 mg PO q12h for 1 week
Alternative Regimen
Ciprofloxacin 400 mg IV q12h for 1-2 days after clinical improvement
OR
Ofloxacin 400 mg iv q12h for 1-2 days after clinical improvement
OR
Spectinomycin 2 g IM q12h for 1-2 days after clinical improvement
FOLLOWED BY
Ciprofloxacin 500 mg po q12h for 1 week
OR
Ofloxacin 400 mg po q12h for 1 week
Haemophilus influenzae
Preferred Regimen
[[
Alternative Regimen
[[
OR
[[
Mycobacterium tuberculosis
Preferred Regimen
Isoniazid for 2 months
PLUS
Rifampin for 2 months
OR
Rifabutin for 2 months
PLUS
Pyrazinamide for 2 months
FOLLOWED BY
Isoniazid for 4-7 months
PLUS
Rifampin for 4-7 months
OR
Rifabutin for 4-7 months
Borrelia burgdorferi
Preferred Regimen
[[
Alternative Regimen
[[
OR
[[
Treponema pallidum
Preferred Regimen
[[
Alternative Regimen
[[
OR
[[
T. whipplei
Preferred Regimen
[[
Alternative Regimen
[[
OR
[[
Nocardia
Preferred Regimen
[[
Alternative Regimen
[[
OR
[[

Pathogen-Based Therapy — Fungi

▸ Click on the following categories to expand treatment regimens.

Fungi

  ▸  Candida

  ▸  Coccidioides

  ▸  Blastomyces

  ▸  Histoplasma

  ▸  Sporothrix

  ▸  Aspergillus

Candida
Preferred Regimen
Amphotericin B deoxycholate 0.5-1 mg/kg/day for 2-3 weeks
FOLLOWED BY
Fluconazole to complete a total duration of therapy of 6-12 months.
Preferred Regimen
Itraconazole 400 mg/day for at least 12 months
Aspergillus
Preferred Regimen
Voriconazole

Pathogen-Based Therapy in Patients with Prosthetic Joint — Bacteria Adapted from Diagnosis and Management of Prosthetic Joint Infection CID 2013:56[2]

▸ Click on the following categories to expand treatment regimens.

Bacteria

  ▸  Staphylococci, oxacillin-susceptible

  ▸  Staphylococci, oxacillin-resistant

  ▸  Enterococcus spp, penicillin-susceptible

  ▸  Enterococcus spp, penicillin-resistant

  ▸  Pseudomonas aeruginosa

  ▸  Enterobacter spp

  ▸  Enterobacteriaceae

Staphylococci, oxacillin-susceptible
Preferred Regimen
Nafcillin 1.5-2 g IV q4-6h
OR
Cefazolin 1–2 g IV q8 h
OR
Ceftriaxone 1–2 g IV q24h
Alternative Regimen
Vancomycin IV 15 mg/kg q12h
OR
Daptomycin 6 mg/kg IV q24h
OR
Linezolid 600 mg PO/IV q12h
Staphylococci, oxacillin-resistant
Preferred Regimen
Vancomycin 15 mg/kg IV q12h
Alternative Regimen
Daptomycin 6 mg/kg IV q24h
OR
Linezolid 600 mg PO/IV q12h
Enterococcus spp, penicillin-susceptible
Preferred Regimen
Penicillin G 20-40 MU IV q24h continuously or divided in 6 doses
Alternative Regimen
Vancomycin IV 15 mg/kg q12h
OR
Daptomycin 6 mg/kg IV q24h
OR
Linezolid 600 mg PO/IV q12h
Enterococcus spp, penicillin-resistant
Preferred Regimen
Vancomycin IV 15 mg/kg q12h
Alternative Regimen
Daptomycin 6 mg/kg IV q24h
OR
Linezolid 600 mg PO/IV q12h
Pseudomonas aeruginosa
Preferred Regimen
Cefepime 2 g IV q12 h
OR
Meropenem 1 g IV q8 h
Alternative Regimen
Ciprofloxacin 750 mg PO q12h or 400 mg IV q12h
OR
Ceftazidime 2 g IV q8h
Enterobacter spp
Preferred Regimen
Cefepime 2 g IV q12h
OR
Ertapenem 1 g IV q24 h
Alternative Regimen
Ciprofloxacin 750 mg PO q12h or 400 mg IV q12h
Preferred Regimen
[[
Alternative Regimen
[
  1. . doi:10.1016/S0140-6736(09)61595-6. Check |doi= value (help). Missing or empty |title= (help)
  2. Osmon, D. R.; Berbari, E. F.; Berendt, A. R.; Lew, D.; Zimmerli, W.; Steckelberg, J. M.; Rao, N.; Hanssen, A.; Wilson, W. R. (2012). "Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guidelines by the Infectious Diseases Society of America". Clinical Infectious Diseases. 56 (1): e1–e25. doi:10.1093/cid/cis803. ISSN 1058-4838.